ALTIMMUNE, INC. Net Fee Amt
ALTIMMUNE, INC. (ALT) had Net Fee Amt of $298.06 as of 2026-05-11, per its S-8 filed 2026-05-13.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-05-13
- 2026-05-11: Net Fee Amt $298.06.
- 2026-04-22: Net Fee Amt $8.98K.
| Period end | Net Fee Amt |
|---|---|
| 2026-05-11 | $298.06 S-8 · filed 2026-05-13 |
| 2026-04-22 | $8.98K S-3MEF · filed 2026-04-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |